Shares of NASDAQ RVMD traded down $0.84 during trading on Wednesday, hitting $40.50. The company had a trading volume of 1,287,715 shares, compared to its average volume of 1,275,704. The business's 50-day moving average is $42.35 and its 200 day moving average is $46.28. The company has a market cap of $6.81 billion, a P/E ratio of -11.28 and a beta of 1.45. Revolution Medicines has a 52 week low of $29.00 and a 52 week high of $62.40.

A number of brokerages recently weighed in on RVMD. Guggenheim upped their target price on shares of Revolution Medicines from $82.00 to $87.00 and gave the stock a "buy" rating in a research report on Tuesday, December 3rd. JPMorgan Chase & Co. lifted their target price on Revolution Medicines from $63.00 to $71.00 and gave the company an "overweight" rating in a research note on Tuesday, December 3rd. UBS Group boosted their price target on Revolution Medicines from $65.00 to $71.00 and gave the stock a "buy" rating in a research note on Wednesday, January 8th. Wedbush reissued an "outperform" rating and set a $70.00 target price on shares of Revolution Medicines in a report on Monday, December 2nd. Finally, HC Wainwright raised their price objective on Revolution Medicines from $64.00 to $72.00 and gave the company a "buy" rating in a report on Wednesday, December 4th. Eleven analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of "Buy" and an average target price of $66.25.

Check Out Our Latest Report on Revolution Medicines

In related news, COO Margaret A. Horn sold 4,329 shares of Revolution Medicines stock in a transaction dated Monday, December 16th. The stock was sold at an average price of $45.40, for a total transaction of $196,536.60. Following the sale, the chief operating officer now directly owns 127,991 shares of the company's stock, valued at $5,810,791.40. This trade represents a 3.27 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Thilo Schroeder purchased 1,304,347 shares of the company's stock in a transaction that occurred on Thursday, December 5th. The stock was acquired at an average cost of $46.00 per share, with a total value of $59,999,962.00. Following the transaction, the director now directly owns 2,096,612 shares of the company's stock, valued at approximately $96,444,152. This represents a 164.64 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders sold a total of 18,678 shares of company stock valued at $847,981 over the last quarter. Company insiders own 8.00% of the company's stock.

Revolution Medicines, Inc, a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].

Before you consider Revolution Medicines, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Revolution Medicines wasn't on the list.

While Revolution Medicines currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.